What Barr Laboratories does

Barr Laboratories is a specialty pharmaceutical company engaged in developing, manufacturing, and marketing both generic and proprietary pharmaceuticals. Based in Pomona, United States, the company operates at substantial scale with 10,000+ employees, indicating a sizeable manufacturing and commercial footprint consistent with large-molecule and small-molecule generics production. According to firmographic inputs, the company was founded in 2003, with its corporate website at barrlabs.com. The available source data does not provide direct product lists or technology architecture specifics for Barr Laboratories; instead, the source material is dominated by content from Teva Pharmaceutical Industries (NYSE: TEVA), the publicly traded parent/franchise context that frames Barr's ecosystem. Strategic positioning described in those sources emphasizes an "innovative biopharmaceutical leader powered by a world-class generics business," focused on neuroscience and immunology growth engines alongside biosimilars.

Barr's growth signal from the broader franchise context includes third consecutive year of growth, an acceleration-phase Pivot to Growth strategy, and pipeline advancement evidenced by an NDA submission for Ecopipam (pediatric Tourette Syndrome). The company's GTM and revenue mechanics, including pricing model specifics, customer segments, and distribution channels, are not present in the source data. Barr's customer base within generic pharmaceuticals would typically consist of wholesalers, pharmacy chains, hospital systems, and group purchasing organizations, but no first-party logos or segment mix data are provided in the inputs. Revenue figures are also not disclosed in the source material, with the available extraction explicitly noting "No revenue figure available in the source data provided." An M&A signal is present: Barr acquired Endeavor Pharmaceuticals on 2003-12-04 (recorded acquisition amount of $35 million in the description field, though the raw amount field shows a data anomaly of $35,000,000,000,000).

Name

Barr Laboratories

Legal name

Teva Pharmaceutical Industries Ltd.

Website

https://barrlabs.com

Company type

Public

Founded year

1901

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Barr Laboratories is a specialty pharmaceutical company in Pomona, United States, that develops, manufactures, and markets generic and proprietary drugs, operating at 10,000+ employee scale within the broader Teva biopharmaceutical ecosystem.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Generic pharmaceuticals
• Specialty pharmaceuticals
• Drug manufacturing
• Proprietary drugs
• Pharmaceutical development

Headquarters

HQ city

Pomona

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Core offering

Barr Laboratories is a specialty pharmaceutical company that develops, manufactures, and markets both generic and proprietary pharmaceutical products. The firm operates large-scale production capacity from its base in Pomona, U.S., and combines drug development with manufacturing to deliver specialty pharmaceutical products.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic pharmaceuticals Specialty generic drug products developed and manufactured by Barr Laboratories for distribution to pharmaceutical wholesalers, pharmacies, and healthcare providers.
• Proprietary pharmaceuticals Specialty proprietary (branded) drug products developed and manufactured by Barr Laboratories for distribution to pharmaceutical wholesalers, pharmacies, and healthcare providers.

Quantifiable outcome

• Brand shareholders collectively gained over $1.8 billion while top generic shareholders lost over $400 million around settlement announcements in high-common-ownership cases

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights4 records

Direct peers

• Aurobindo Pharma: India-based generics manufacturer with large US business across oral solids, injectables, and APIs. Comparable to Barr's generic FDF manufacturing focus and US distribution scale.
• Mallinckrodt: Specialty pharmaceuticals manufacturer with generics and branded specialty franchises. Comparable to Barr's mix of generic manufacturing and proprietary/specialty positioning.
• Endo International: Specialty and generic pharmaceutical company with significant US footprint, including sterile injectables and generics. Comparable to Barr's generics + specialty dual model and US-centric distribution.
• Teva Pharmaceutical Industries: Parent/generics platform with a world-class generics business spanning branded and specialty pharmaceuticals. The most direct comparable because the source profile identifies Teva as the operating entity for Barr and shares the same generics + specialty model.
• Viatris: Formed via Mylan-Upjohn combination, Viatris is a top global generics manufacturer with a sizable specialty portfolio. Directly comparable to Barr in generics-led business model and US distribution footprint.
• Sandoz (Novartis): Sandoz is one of the world's largest generic and biosimilar manufacturers, with broad US generic footprint. Comparable to Barr in core generic manufacturing and product portfolio breadth.
• Dr. Reddy's Laboratories: India-based integrated pharmaceutical company with global generics and proprietary products. Comparable to Barr across generic finished dosage manufacturing, US commercial presence, and specialty pipeline.
• Sun Pharmaceutical Industries: India-based global generic manufacturer with the largest US generics market share by prescriptions. Comparable to Barr in vertical integration from API to finished dosage and in US generics distribution.
• Lupin Pharmaceuticals: India-based pharmaceutical manufacturer with significant US generics business and emerging specialty pipeline. Comparable to Barr's generics-led model with proprietary/specialty extensions and US commercial reach.
• Apotex: Canadian-based generic pharmaceutical manufacturer with significant US sales. Closely comparable to Barr as a privately-held (or recently restructured) generics-led manufacturer with proprietary/specialty extensions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/tevapharm
• Facebookfacebook.com/tevapharm
• LinkedInlinkedin.com/company/5239

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Barr Laboratories